AstraZeneca (AZN) stock surged early Thursday after the pharma company reported core earnings of $2.09 per share on $14.89 billion in fourth-quarter sales.
↑ X NOW PLAYING How To Buy Stocks: IBD's Four Pillars Of InvestingBoth measures beat expectations, according to FactSet. Earnings rocketed 44% on a strict, as-reported basis, while sales climbed 24%.
For the year, AstraZeneca guided to sales growth in the high single-digit percentage range. The company also projects core earnings growth at a low double-digit percentage. Wall Street projected earnings of $9.27 per share on $56.79 billion in sales.
In premarket trades on the stock market today, AstraZeneca stock jumped more than 4.5% to 74.17.
More to follow.
YOU MAY ALSO LIKE:
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion
Merck Stock Plummets 9% As Gardasil Dynamics, 2025 Guidance Weigh On Shares
Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists
Want More IBD Insights? Subscribe To Our Investing Podcast!
Get Timely Buy & Sell Alerts With IBD Leaderboard
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。